Article
Celltrion Targets European Secukinumab Market With EMA Filing For CT-P55
Celltrion has submitted a Marketing Authorization Application to the European Medicines Agency for CT-P55, its biosimilar candidate to Novartis' blockbuster drug COSENTYX. The application seeks approval across all European indications including multiple autoimmune conditions, following earlier regulatory filings in Canada and South Korea.
Goodwin Procter LLP